Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy

NextCure (NXTC) agreed to an all-stock merger with privately held Avere Therapeutics, taking Avere public. The deal includes $320 million in financing to advance Avere’s lead oral IL-23 therapy, AVR-001, and should be supportive for development funding and near-term valuation optics. Overall, the transaction is a positive catalyst given the scale of committed financing alongside the public listing of the target.

Analysis

NextCure (NXTC) agreed to an all-stock merger with privately held Avere Therapeutics, taking Avere public. The deal includes $320 million in financing to advance Avere’s lead oral IL-23 therapy, AVR-001, and should be supportive for development funding and near-term valuation optics. Overall, the transaction is a positive catalyst given the scale of committed financing alongside the public listing of the target.